Leading provider of Fertility Services in the Middle East and India, ART Fertility Clinics welcomes on board David Jimenez.
David Jimenez is a seasoned executive with extensive experience in the healthcare industry, including a decade-long tenure as CEO of Igenomix, a global leader in Advanced Molecular Diagnostics in the field of Reproductive Medicine.
Holding a degree in Business Science and an MBA from ESADE Business School, David possesses over 30 times extensive international experience in both consumer goods and healthcare industriousness and has demonstrated his leadership capacities across Europe and the Americas, including the Middle East, Switzerland, USA, Mexico, and Spain. During his time at Igenomix, David served as Managing Director of Corporacion Dermoestética, a leading provider of Cosmetic Surgery and other medical treatments in Spain and Portugal from 2008 to 2011. He also held a series of elderly positions at Philip Morris International, including Marlboro Brand Manager for Spain and Mexico and Business Development and Planning Manager for the Latin America Region.
With his strategic acumen, deep industry expertise and vast international experience, David’s presence in the Board will be invaluable in ART Fertility Clinics' ambitious expansion across multiple geographies and new services.
As the former CEO of Igenomix, David oversaw the company’s meteoric rise from a single lab in Spain to a global entity with 26 laboratories worldwide. Under his guidance, Igenomix, which originated as a spin- off from IVI, flourished to become a leading provider of genetic testing services in Reproductive Medicine.
David Jiminez said: “Joining the ART Fertility Clinics' Board of Directors is a privilege and an opportunity to contribute to a field that has a profound impact on people's lives. The clinic's dedication to excellence and its patient-first approach resonates deeply with my professional philosophy. I am eager to help ART continue its journey as a global leader in fertility care.”
Starting from the spin- off from IVI in 2011, David steered the company through three significant transactions including its acquisition by Charme Capital partners in 2016, a subsequent sale of a majority stake to EQT, the global private equity investor, and finally culminating in its sale to Vitrolife in 2021 for $1.5 billion.
A portfolio company of Gulf Capital, ART Fertility Clinics is renowned for its high success rates, proprietary research and innovations, and a commitment to providing the highest quality of care.
"We value Mr Jimenez’s leadership and international perspective. His deep understanding of the healthcare landscape will be a significant asset as ART Fertility Clinics continues to expand globally," said Suresh Soni, the Global Chief Executive Officer, ART Fertility Clinics. "We are thrilled to have such a visionary joining our ranks."
Since its inception, ART Fertility Clinics has been at the forefront of Fertility and Reproductive Health, offering advanced treatments and personalised care under the leadership of CEO Mr. Suresh Soni and Group Medical Director Professor Dr Human Fatemi. With a team of highly skilled physicians utilising state- of- the- art technology, ART Fertility Clinics is dedicated to providing the highest level of compassionate and individualised care.